To our knowledge, this is the first report of the carboplatin/paclitaxel/trastuzumab regimen followed by one year of maintenance trastuzumab in a patient with ERBB2-amplified mucinous ovarian carcinoma and the first report of a durable remission in this setting. The gene discussed is ERBB2; the disease is ovarian mucinous adenocarcinoma.